Bevacizumab in clinical practice: Prescribing appropriateness relative to national indications and safety

Martina Bonifazi, Marta Rossi, Lorenzo Moja, Vincenzo Davide Scigliano, Matteo Franchi, Carlo la Vecchia, Carlo Zocchetti, Eva Negri

Research output: Contribution to journalArticle

Abstract

The aim of this study was to describe the clinical use of bevacizumab in Lombardy (9.5 million inhabitants), Italy, during 2006 -2007 in patients with metastatic colorectal cancer (mCRC) to evaluate compliance with the Italian Medicine Agency (AIFA) indications, the incidence of adverse events, and the survival rate. We performed computerized record linkage among three different Lombardy health care databases: File F registry, Regional discharge database, and Registry Office records. Patients were classified into approved and offlabel uses according to the AIFA indications. Treatment with bevacizumab was administered to 780 patients, of whom 81.7% (n = 637) had mCRC. Among these, 37.8% (n = 241) of patients received the drug in observance of AIFA indications. Overall, =10% of patients had serious treatment-related toxicities (fistula, 3.5%; venous thromboembolism, 2.8%; hemorrhage, 1.9%; intestinal perforation and arterial thromboembolism,

Original languageEnglish
Pages (from-to)117-124
Number of pages8
JournalThe oncologist
Volume17
Issue number1
DOIs
Publication statusPublished - 2012

    Fingerprint

Keywords

  • Appropriateness
  • Bevacizumab
  • Metastatic colorectal cancer
  • Safety
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bonifazi, M., Rossi, M., Moja, L., Scigliano, V. D., Franchi, M., la Vecchia, C., Zocchetti, C., & Negri, E. (2012). Bevacizumab in clinical practice: Prescribing appropriateness relative to national indications and safety. The oncologist, 17(1), 117-124. https://doi.org/10.1634/theoncologist.2011-0184